Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts

Cochrane Database of Systematic Reviews

Volumn 2015, Issue 7, 2015, Pages

  Tanner, Nicola C ^a   Da Silva, Anthony ^a  

^a WREXHAM MAELOR HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; DIPYRIDAMOLE; FISH OIL; PLACEBO; SULFINPYRAZONE; TICLOPIDINE; VONAPANITASE; WARFARIN; ANTITHROMBOCYTIC AGENT;

ADJUVANT THERAPY; ARTERIOVENOUS FISTULA; ARTERIOVENOUS GRAFT; ARTERIOVENOUS SHUNT; CLINICAL EFFECTIVENESS; END STAGE RENAL DISEASE; EVIDENCE BASED MEDICINE; HUMAN; INTENTION TO TREAT ANALYSIS; LENGTH OF STAY; PRIORITY JOURNAL; RENAL REPLACEMENT THERAPY; REVIEW; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE; VASCULAR PATENCY; ADJUVANT CHEMOTHERAPY; ADVERSE EFFECTS; DRUG EFFECTS; KIDNEY FAILURE, CHRONIC; META ANALYSIS; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ARTERIOVENOUS SHUNT, SURGICAL; CHEMOTHERAPY, ADJUVANT; HUMANS; KIDNEY FAILURE, CHRONIC; PLATELET AGGREGATION INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RENAL DIALYSIS; TICLOPIDINE; VASCULAR PATENCY;

EID: 84957413766     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD002786.pub3     Document Type: Review

References (60)

1. Andrassy K, Malluche H, Bornefeld H, Comberg M, Ritz E, Jesdinsky H, et al. Prevention of p.o. clotting of av. cimino fistulae with acetylsalicyl acid: results of a prospective double blind study. Klinische Wochenschrift 1974;52(7):348-9.
2. Crowther MA, Clase CM, Margetts PJ, Julian J, Lambert K, Sneath D, et al. Low-intensity warfarin is ineffective for the prevention of PTFE graft failure in patients on hemodialysis: a randomized controlled trial. Journal of the American Society of Nephrology 2002;13(9):2331-7.
3. Dember LM, Beck GJ, Allon M, Delmez JA, Dixon BS, Greenberg A, et al for the Dialysis Access Consortium Study Group. Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial. JAMA 2008;299(18):2164-71.
4. Dwivedi AJ, Roy-Chaudhury P, Peden EK, Browne BJ, Ladenheim ED, Scavo VA, et al. Application of human type I pancreatic elastase (PRT-201) to the venous anastomosis of arteriovenous grafts in patients with chronic kidney disease. Journal of Vascular Surgery 2014;15(5):376-84.
5. Fiskerstrand CE, Thompson IW, Burnet ME, Williams P, Anderton JL. Double-blind randomized trial of the effect of ticlopidine in arteriovenous fistulas for haemodialysis. Artificial Organs 1985;9(1):61-3.
6. Ghorbani A, Aalamshah M, Shahbazian H, Ehsanpour A, Aref A. Randomized controlled trial of clopidogrel to prevent primary arteriovenous fistula failure in hemodialysis patients. Indian Journal of Nephrology April 2009;19(2):57-61.
7. Grontoft KC, Mulec H, Gutierrez A, Olander R. Thromboprophylactic effect of ticlopidine in arteriovenous fistulas for haemodialysis. Scandinavian Journal of Urology and Nephrology 1985;19(1):55-7.
8. Grontoft KC, Larsson R, Mulec H, Weiss LG, Dickinson JP. Effects of ticlopidine in A-V fistula surgery in uremia. Fistual Study Group. Scandinavian Journal of Urology and Nephrology 1998;32(4):276-83.
9. Harter HR, Burch JW, Majerus PW, Stanford N, Delmez JA, Anderson CB, et al. Prevention of thrombosis in patients on haemodialysis by low-dose aspirin. New England Journal of Medicine 1979;301(11):577-9.
10. Hye RJ, Peden EK, O'Connor TP, Browne BJ, Dixon BS, Schanzer AS, et al. Human type I pancreatic elastase treatment of arteriovenous fistulas in patients with chronic kidney disease. Journal of Vascular Surgery 2014;60(2):454-61.
11. Anon. Fish oil inhibition of stenosis in haemodialysis grafts study. http://www.isrctn.com/ISRCTN15838383 2007.
12. Lok CE, Allon M, Donnelly S, Dorval M, Hemmelgarn B, Moist L, et al. Design of the fish oil inhibition of stenosis in hemodialysis grafts (FISH) study. Clinical Trials 2007;4(4):357-67.
13. Lok CE, Moist L, Hemmelgarn BR, Tonelli M, Vazquez MA, Dorval M, et al for the Fish Oil Inhibition of Stenosis in Hemodialysis Grafts (FISH) Study Group. Effect of fish oil supplementation on graft patency and cardiovascular events among patients with new synthetic arteriovenous hemodialysis grafts. JAMA 2012;307(17):1809-16.
14. Michie DD, Wombolt DG. Use of sulfinpyrazone to prevent thrombus formation in arteriovenous fistulas and bovine grafts of patients on chronic hemodialysis. Current Therapeutic Research, Clinical and Experimental 1977;22(1):196-204.
15. Peden EK, Leeser DB, Dixon BS, El-Klatib MT, Roy-Chaudhury P, Lawson JH, et al. A multi-center, dose-escalation study of human type I pancreatic elastase (PRT-201) administered after arteriovenous fistula creation. Journal of Vascular Access 2013;14(2):143-51.
16. Schmitz PG, McCloud LK, Reikes ST, Leonard CL, Gellens ME. Prophylaxis of hemodialysis graft thrombosis with fish oil: double-blind, randomized, prospective trial. Journal of the American Society of Nephrology 2002;13:184-90.
17. Sreedhara R, Himmelfarb J, Lazarus JM, Hakim RM. Anti-platelet therapy in graft thrombosis: results of a prospective, randomized double blind study. Kidney International 1994;45(5):1477-83.
18. Albert FW, Schmidt U, Harzer R. Postoperative thromboprophylaxis for cimino-fistulae with sulfinpyrazone in comparison to acetylsalicylic acid. Krankenhausarzt 1978;51:712-8.
19. Alexopoulos D, Panagiotou A, Xanthopoulou I, Komninakis D, Kassimis G, Davlouros P, et al. Antiplatelet effects of prasugrel vs. double clopidogrel in patients on hemodialysis and with high on-treatment platelet reactivity. Journal of Thrombosis and Haemostasis 2011;9(12):2379-85.
20. Bhomi KK, Shrestha S, Bhattachan CL. Role of systemic anticoagulation in patients undergoing vascular access surgery. Nepal Medical College Journal: NMCJ 2008;10(4):222-4.
21. Chen L, Ling YS, Lin CH, Guan TJ. Combined use of heparin and anisodamine reduces the risk of early thrombosis in native arteriovenous fistula. Vascular 2013;21(6):369-74.
22. D'Ayala M, Smith RM, Martone C, Briggs W, Deitch JS, Wise L. The effect of systemic anticoagulation in patients undergoing angioaccess surgery. Annals of Vascular Surgery 2008;22:11-5.
23. de Fijter CWH, Popp-Snijders C, Oe LP, Tran DD, van der Meulen J, Donker AJM. Does additional treatment with fish oil mitigate the side effects of recombinant human erythropoietin in dialysis patients?. Haematologia 1995;80:332-4.
24. Dixon BS, Beck GJ, Dember LM, Vazquez MA, Greenberg A, Delmez JA, et al. Use of aspirin associates with longer primary patency of hemodialysis grafts. Journal of the American Society of Nephrology: JASN. 2011;22(4):773-81.
25. Dixon BS, Beck GJ, Vazquez MA, Greenberg A, Delmez JA, Allon M, et al. Effect of dipyridamole plus aspirin on hemodialysis graft patency. New England Journal of Medicine 2009;360:2191-201.
26. Dulude H, Kaplan M, Odland M, Marbury T, Hoggard JG, Ploth D, et al. Escalating single doses of CJC-1004, a locally acting antithrombotic agent in hemodialysis patients with vascular access occlusion. Journal of the American Society of Nephrology 2001;12:287A.
27. Fuster V, Charlton P, Boyd A. Clinical protocol. A phase IIb, randomized, multicenter, double-blind study of the efficacy and safety of Trinam (EG004) in stenosis prevention at the graft-vein anastomosis site in dialysis patients. Human Gene Therapy 2001;12(16):2025-7.
28. Janicki K, Bojarska SA, Pietura R, Janicka L. Preventive effects of ticlopidine on the incidence of late A-V fistula thrombosis complications in haemodialyses patients. Annales Universitatis Mariae Curie Sklodowska Sectio D: Medicina 2003;58:215-8.
29. Kaegi A, Pineo GF, Shimizu A, Trivedi H, Hirsh J, Gent M. The role of sulfinpyrazone in the prevention of arterio-venous shunt thrombosis. Circulation 1975;52(3):497-9.
30. Kaufman JS, O'Connor TZ, Zhang JH, Cronin RE, Fiore LD, Ganz MB, et al. Veterans Affairs Cooperative Study Group on Hemodialysis Access Graft Thrombosis. Randomized controlled trial of clopidogrel plus aspirin to prevent hemodialysis access graft thrombosis. Journal of the American Society of Nephrology 2003;14(9):2313-21.
31. Kooistra MP, van Es A, Marx JJM, Hertsig MLA, Struyvenberg A. Low-dose aspirin does not prevent thrombovascular accidents in low-risk hemodialysis patients during treatment with recombinant human erythropoietin. Nephrology, Dialysis, Transplantation 1994;9:1115-20.
32. Krasinski Z, Dzieciuchowicz L, Kulesza J, Pietrzak I, Gabriel M, Krasinka B, et al. Influence of long-term therapy with low molecular weight heparin on patency of arterio-venous fistula for hemodialysis. ERA - EDTA ELI Congress Abstracts. 2004:360.
33. Lee YK, Koo JR, Kim JK, Park II, Joo MH, Yoon JW, et al. Effect of route of EPO administration on hemodialysis arteriovenous vascular access failure: a randomized controlled trial. American Journal of Kidney Diseases 2009;53(5):815-22.
34. Lin CC, Chang CF, Lai MY, Chen TW, Lee PC, Yang WC. Far-infrared therapy: a novel treatment to improve access blood flow and unassisted patency of arteriovenous fistula in hemodialysis patients. Journal of the American Society of Nephrology 2007;18(3):985-92.
35. Lin CC, Yang WC. Far infrared therapy improves arteriovenous fistula maturation. Nephrology Dialysis Transplantation 2013;28:i226-7.
36. Lin CC, Yang WC, Chen MC, Liu WS, Yang CY, Lee PC. Effect of far infrared therapy on arteriovenous fistula maturation: an open-label randomized controlled trial. American Journal of Kidney Diseases 2013;62(2):304-11.
37. Malovrh M. Expansion of blood volume increases the primary patency rate of arteriovenous fistulas for hemodialysis in patients with critical arterial quality. Therapeutic Apheresis and Dialysis 2009;13(4):345-9.
38. Mileti M, De Petri G, Bacchi M, Ogliari V, Pecchini F, Bufano G, et al. A trial to evaluate the efficacy of picotamide in preventing thrombotic occlusion of the vascular access in hemodialysis patients. Journal of Nephrology 1995;8(3):167-72.
39. Radmilovic A, Boric Z, Naumovic T, Stamenkovic M, Musikic P. Shunt thrombosis prevention in hemodialysis patients - A double-blind, randomized study: pentoxifylline vs placebo. Angiology 1998;38(7):499-506.
40. Rouzrokh M, Reza Abbasi M, Reza Mirshemirani A, Reza Sobhiyeh M. The effect of antiplatelet drugs on the patency rate of arterio-venous fistulae in hemodialysis patients. Iranian Journal of Pharmaceutical Research 2010;9(4):451-7.
41. Taber T, Maikranz P, Haag B, Dilley R, Gaylord G. Hemodialysis vascular graft stenosis may be altered by low-molecular weight dextran (lmd), but not by aspirin (asa) [abstract]. Journal of the American Society of Nephrology 1992; Vol. 3, issue 3:397.
42. Trimarchi H, Young P, Forrester M, Schropp J, Pereyra H, Freixas E. Clopidogrel diminishes hemodialysis acces graft thrombosis. Nephron. Clinical Practice 2006;102:c128-32.
43. Wang BR, Rowe VL, Wan Ham S, Han S, Patel K, Weaver FA, et al. A prospective clinical evaluation of the effects of intraoperative systemic anticoagulation in patients undergoing arteriovenous fistula surgery. The American Surgeon 2010;76:1112-4.
44. Wasse H, Huang R, Long Q, Zhao Y, Singapuri S, McKinnon W, et al. Very high-dose cholecalciferol and arteriovenous fistula maturation in ESRD: a randomized, double-blind, placebo-controlled pilot study. Journal of Vascular Access 2014;15(2):88-94.
45. Yuto J, Ehara Y, Shibata K, Iwamoto T, Yasuda G, Yatsu K, et al. Effect of sarpogrelate on fistula patency of forearm arteriovenous anastomosis in uremic patients. Kidney Research and Clinical Practice 2012;31:A86.
46. Irish A. A randomised, double-blind, placebo-controlled, factorial-design trial to assess the effect of aspirin and fish oil in the prevention of early thrombosis in arterio-venous fistulae in patients with Stage IV or V chronic kidney disease requiring haemodialysis - FAVOURED (Fish oil and Aspirin in Vascular access OUtcomes in REnal Disease). Cochrane Renal Group Prospective Trials Register [http://www.cochranerenal.org./dbsearch.php.] 2007.
47. Irish A. Baseline characteristics of the patients participating in the favoured trial. Nephrology 2010;15:35.
48. Irish A. Fish oil and aspirin in vascular access outcomes in renal disease. Australasian Kidney Trials Network [http://www.uq.edu.au./aktn./index.html.] 2007.
49. Irish A, Dogra G, Mori T, Beller E, Heritier S, Hawley C, et al. Preventing AVF thrombosis: The rationale and design of the Omega-3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. http://www.biomedcentral.com/1471-2369/10/1 (accessed 23 March 2015). [DOI: 10.1186/1471-2369-10-1]
50. Churchill DN, Taylor DW, Cook RJ, Laplante P, Barre P, Cartier P, et al. Canadian hemodialysis morbidity study. American Journal of Kidney Disease 1992;19(3):214-34.
51. Coleman CI, Tuttle LA, Teevan C, Baker WL, White CM, Reinhart KM. Antiplatelet agents for the prevention of arteriovenous fistula and graft thrombosis: a meta analysis. International Journal of Clinical Practice August 2010;9:1239-44.
52. Anonymous. NKF-DOQI clinical practice guidelines for vascular access. National Kidney Foundation - Dialysis Outcomes Quality Initiative. American Journal of Kidney Diseases 1997;30 Suppl 3:150-91.
53. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
54. Kanterman RY, Vesely TM, Pilgram TK, Guy BW, Windus DW, Picus D. Dialysis access grafts: anatomic localisation of venous stenosis and results of angioplasty. Radiology 1995;195(1):135-9.
55. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. Journal of the American Statistical Association 1958;53:457-81.
56. Metha S. Statistical summary of clinical results of vascular access procedures for haemodialysis. In: Sommer BG, Henry ML editor(s). Vascular Access for Hemodialysis-II (Chapter 11). W L Gore, 1991:145-57.
57. Pisoni RL, Young EW, Dykstra DM, Greenwood RN, Hecking E, Gillespie B, et al. Vascular access use in Europe and the United States: results from the DOPPS. Kidney International 2002;61(1):305-16.
58. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
59. Da Silva AF, Escofet X, Rutherford PA. Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts. Cochrane Database of Systematic Reviews 2003, Issue 2. [DOI: 10.1002/14651858.CD002786]
60. Osborn G, Escofet X, Da Silva A. Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts. Cochrane Database of Systematic Reviews 2008, Issue 4. [DOI: 10.1002/14651858.CD002786.pub2]